bluebird bio (BLUE) PT Raised to $35 at BMO Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Bristol-Myers Squibb (BMY), bluebird bio (BLUE) Announces FDA Approval for Abecma for Relapsed or Refractory Multiple Myeloma
March 29, 2021 6:29 AM EDTLate Friday, Bristol-Myers Squibb (NYSE: BMY) and bluebird bio, Inc. (Nasdaq: BLUE) today announced that the U.S. Food and Drug Administration (FDA) has approved Abecma (idecabtagene vicleucel; ide-cel) as the first B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. Abecma is a personalized immune cell therapy approved as a... More
bluebird bio (BLUE) PT Raised to $70 at Mizuho Securities on Abecma Approval
March 29, 2021 6:26 AM EDTMizuho Securities analyst Difei Yang raised the price target on bluebird bio (NASDAQ: BLUE) to $70.00 (from $69.00) while maintaining a Buy rating.
The analyst commented, "The FDA approved Ide-Cel (Abecma) on Friday, making this the first BCMA CAR-T therapy available for the treatment of multiple... More
bluebird bio (BLUE) PT Raised to $72 at SVB Leerink
March 29, 2021 6:24 AM EDTSVB Leerink analyst Mani Foroohar raised the price target on bluebird bio (NASDAQ: BLUE) to $72.00 (from $69.00) while maintaining a Outperform rating.... More
Morgan Stanley Discusses the Impact and Pricing of Bluebird Bio's (BLUE) Abecma (bb2121)
March 29, 2021 6:06 AM EDTMorgan Stanley analyst Matthew Harrison reiterated an Equalweight rating and $45.00 price target on bluebird bio (NASDAQ: BLUE) after the FDA approved Abecma (bb2121) in patients with relapsed/refractory MM who have previously received 4+ therapies. Abecma is a first-in-class anti-BCMA CART therapy with a... More
